Ertapenem disodium

立即咨询

Ertapenem disodium

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	153832-38-3
规格:	≥98%

包装与价格：

包装	价格(元)
25mg	电议
50mg	电议
100mg	电议
250mg	电议
500mg	电议

产品介绍

理化性质和储存条件

Molecular Formula: C22H23N3Na2O7S;

Molecular Weight: 519.48

In Vitro	Ertapenem disodium (MK-0826) (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively[1]. Cell Viability Assay[1] Cell Line: B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055) Concentration: 0-100 μg/mL approximately Incubation Time: 48 h Result: Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.
In Vivo	Ertapenem disodium (MK-0826) (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows> 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg[2]. Ertapenem disodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of<0.25 2="" 10="" 120="" .="" animal="" model:="" s.="" aureus="" thigh="" tissue="" infection="" model="" dosage:="" kg="" given="" at="" administration:="" subcutaneous="" injection="" 0.5="" ml="" after="" result:="" displayed="">3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg. Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg. Animal Model: Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)[2] Dosage: 0-3 mg/kg approximately Administration: Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection) Result: Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of<0.25 mg/kg/dose. Animal Model: CD-1 mice, rats[2] Dosage: 10 mg/kg approximately Administration: Intraperitoneal injection (pharmacokinetic assay) Result: Exhibited an AUC0-∞ ranging from 1.8-21.82 μgohr/mL in tissue in mice following a 10-mg/kg i.p. dose. Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15μgohr/mL

In Vitro

Ertapenem disodium (MK-0826) (0-100 μg/mL approximately, 48 h) is active against 99.1% of all anaerobes with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and MIC’s ≥8 μg/mL for B.fragilis and B.vulgatus species, respectively[1]. Cell Viability Assay[1] Cell Line: B. fragilis (ATCC 25285), B. thetaiotaomicron (ATCC 29741), and Eubacterium lentum (ATCC 43055) Concentration: 0-100 μg/mL approximately Incubation Time: 48 h Result: Inhibited 99.1% of all isolate with a mode MIC of 0.12 μg/mL and MIC90 of 1 μg/mL, and 98.8% of the isolates were susceptible among the B. fragilis group.

In Vivo

Ertapenem disodium (MK-0826) (Subcutaneous injection, 0-10 mg/kg, 0-120 h after infection, S. aureus thigh tissue infection model) shows> 3 log10 CFU reduction of organism at 10 mg/kg, and maintains the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg[2]. Ertapenem disodium (Subcutaneous injection, 4h after infection, systemic infection model) is active against all gram-positive organisms, and is also active against gram-negative organisms tested with ED50s of<0.25 2="" 10="" 120="" .="" animal="" model:="" s.="" aureus="" thigh="" tissue="" infection="" model="" dosage:="" kg="" given="" at="" administration:="" subcutaneous="" injection="" 0.5="" ml="" after="" result:="" displayed="">3 log10 CFU reduction of organism compared to non-antibiotic-treated controls at 10 mg/kg. Maintained the activity with 3.3 and 4.4 log10 CFU eliminated at 2 mg/kg. Animal Model: Systemic infection model (DBA/2 female mice, viral antibody-free CD-1 female mice)[2] Dosage: 0-3 mg/kg approximately Administration: Subcutaneous injection (0.5 mL, begin immediately and 4 h after infection) Result: Showed activity against all gram-positive organisms, and also ram-negative organisms tested with ED50s of<0.25 mg/kg/dose. Animal Model: CD-1 mice, rats[2] Dosage: 10 mg/kg approximately Administration: Intraperitoneal injection (pharmacokinetic assay) Result: Exhibited an AUC0-∞ ranging from 1.8-21.82 μgohr/mL in tissue in mice following a 10-mg/kg i.p. dose. Exhibited slow clearance rate with a t1/2β of 3.2 h, Clp of 0.47 mL/min/kg, AUC0-8 of 284.15μgohr/mL